Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography.Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndromeArterial and venous thromboembolism in chronic obstructive pulmonary disease: from pathogenic mechanisms to prevention and treatmentFrom principle to practice: bridging the gap in patient profilingAspirin resistanceAspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphismAntithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsLack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirinAnticoagulants and the propagation phase of thrombin generationTreatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes.The "normal" factor VIII concentration in plasma.Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular eventsActivated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease.Activated factor XI and tissue factor in aortic stenosis: links with thrombin generationThrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor compositionActive tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events.Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.Fibrinogen beta-chain -C148T polymorphism is associated with increased fibrinogen, C-reactive protein, and interleukin-6 in patients undergoing coronary artery bypass graftingDoes diabetes accelerate the progression of aortic stenosis through enhanced inflammatory response within aortic valves?Statins and blood coagulation.Increased Oxidation as an Additional Mechanism Underlying Reduced Clot Permeability and Impaired Fibrinolysis in Type 2 Diabetes.Association of the C-Reactive Protein Gene (CRP) rs1205 C>T Polymorphism with Aortic Valve Calcification in Patients with Aortic Stenosis.Specific changes in circulating cytokines and growth factors induced by exercise stress testing in asymptomatic aortic valve stenosisType 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.Omega-3 polyunsaturated fatty acids increase plasma adiponectin to leptin ratio in stable coronary artery disease.Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosisSystemic blood coagulation activation in acute coronary syndromes.Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke.Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial.Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases.Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses.Atherosclerosis and venous thromboembolism - similarities.Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.Increased bleeding risk in patients with aortic valvular stenosis: From new mechanisms to new therapies.
P50
Q21245672-80AE6407-DA00-4C7A-A4C1-E05C9AABB534Q24185949-CFD93A3F-2BD9-4CEC-B7BD-AA79337D2D1AQ26777500-A12892D7-A4DB-42BC-BAAA-E7CBA89896D9Q27318447-FDE96EBD-2755-4B87-A6C7-9133D3408D45Q28194534-AC177C62-24C7-4A54-9D16-0FAB2778D126Q28194578-70B9647A-413D-4717-8E66-BB7B68211099Q28211940-D1C79920-B66E-4558-9B15-A1027D860A44Q28212411-0A4EE6D8-32DB-4ADE-AEF5-4C3A521F835AQ28742536-D76268AA-2483-4747-9F58-5A98134C97ADQ33564624-E13E1E97-EA02-42E8-BD96-FDF04CA275B0Q34023313-B26FF49F-11C9-4648-8332-D9019A455349Q34159230-3A600CBA-D1C7-4D7B-AD4A-C7A2AE873FABQ34590212-44108A6B-15E4-4EFE-B7F4-518A7FD1EC79Q34692868-20E2236C-2916-4C92-BE57-7596DAEEB252Q35137668-F8F8B48C-51AE-4BC9-AB1E-4FB422FA011BQ35243446-293F0334-D479-4382-B884-2AA3AD0EE7CCQ35293080-CEB46BFD-0B01-440C-8DDD-7EAD36871A6EQ35489598-B9F79496-0290-4AF8-9350-737B41B99C37Q35535747-BFD31D61-0C4E-41F5-B81F-986A1D140505Q35609789-9A6629C9-2A33-44A4-A90E-FDF20FF1BDB3Q35833396-FD790B78-D231-429C-BBE5-E9E7DA6223C9Q35859099-5174F322-CA8E-4EE3-8BC4-FD450A12F79EQ35904561-2494C1FE-A37A-4881-9D6B-E9FEFD6F1069Q35966532-BE22D5BF-D9C6-4995-8C71-61899F68CCD4Q36015232-F0874E1F-715E-4D51-A82B-81854C01FC20Q36247336-EEF1237B-2025-4FBC-9E98-C0C265A98319Q36307529-EE25F8CD-1181-4009-8028-6E746456EF63Q36546041-9FD349D6-4418-49AE-A5B4-04246ADAED1BQ36807512-FC0AA915-9010-4BEB-A947-B461E1EC037AQ37004879-005D9BDA-3B60-4EE9-B1E5-64DE013B09D5Q37043341-3674D399-E0A0-4509-9245-58308B925C1AQ37116951-E5ED841A-D335-4C5A-8984-A0B99FD9FFDBQ37243007-1A6A5A85-3BF6-43E6-9DD3-EF35B2F75E18Q37590174-2DD484D2-F734-4418-B33A-9FC849D3019CQ37915947-EED7705B-6DBF-41E4-A7B2-FD4D97A842FEQ37987647-FDD5BCC1-C2DC-4CDA-826F-F1210667D127Q38176574-A26D6CB7-44B6-407D-BFDB-6E86D30E59F1Q38517821-4D431643-3148-4A4E-BC68-06DFFA7320BAQ38558488-E22C5E26-0231-44F6-ACB0-BA5A2A7DE6D6Q38750596-1E81488A-8CA0-4890-9B73-18EB7A910571
P50
description
Polish physician and researcher
@en
Pools onderzoekster
@nl
polska lekarka, internistka
@pl
name
Anetta Undas
@ast
Anetta Undas
@ca
Anetta Undas
@cs
Anetta Undas
@en
Anetta Undas
@es
Anetta Undas
@ga
Anetta Undas
@gl
Anetta Undas
@hr
Anetta Undas
@hsb
Anetta Undas
@it
type
label
Anetta Undas
@ast
Anetta Undas
@ca
Anetta Undas
@cs
Anetta Undas
@en
Anetta Undas
@es
Anetta Undas
@ga
Anetta Undas
@gl
Anetta Undas
@hr
Anetta Undas
@hsb
Anetta Undas
@it
altLabel
Anetta Iwona Undas
@pl
prefLabel
Anetta Undas
@ast
Anetta Undas
@ca
Anetta Undas
@cs
Anetta Undas
@en
Anetta Undas
@es
Anetta Undas
@ga
Anetta Undas
@gl
Anetta Undas
@hr
Anetta Undas
@hsb
Anetta Undas
@it
P214
P106
P1412
P1559
Anetta Undas
@pl
P21
P214
P27
P31
P3124
P569
1965-01-01T00:00:00Z
P7859
viaf-161823723